Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

ClinicalTrials.gov ID: NCT05243680

Public ClinicalTrials.gov record NCT05243680. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744

Study identification

NCT ID
NCT05243680
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
641 participants

Conditions and interventions

Conditions

Interventions

  • GSK3511294 (Depemokimab) Biological

Biological

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2022
Primary completion
May 18, 2025
Completion
May 18, 2025
Last update posted
Jan 14, 2026

2022 – 2025

United States locations

U.S. sites
29
U.S. states
14
U.S. cities
26
Facility City State ZIP Site status
GSK Investigational Site Mobile Alabama 36608
GSK Investigational Site Lancaster California 93534
GSK Investigational Site Colorado Springs Colorado 80923
GSK Investigational Site Lafayette Colorado 80026
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Hialeah Florida 33013
GSK Investigational Site Loxahatchee Groves Florida 33470
GSK Investigational Site Miami Florida 33144
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Miami Florida 33186
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Savannah Georgia 31406
GSK Investigational Site Normal Illinois 61761
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Ypsilanti Michigan 48197
GSK Investigational Site Northfield New Jersey 08225
GSK Investigational Site Toms River New Jersey 08755
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Gastonia North Carolina 28054
GSK Investigational Site Huntersville North Carolina 28078
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site DuBois Pennsylvania 15801
GSK Investigational Site Allen Texas 75013
GSK Investigational Site Boerne Texas 78006
GSK Investigational Site Dallas Texas 75225
GSK Investigational Site Kerrville Texas 78028
GSK Investigational Site San Antonio Texas 78207
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Bellingham Washington 98225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05243680, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 14, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05243680 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →